Reduced cilia frequencies in human renal cell carcinomas versus neighboring parenchymal tissue

Cilia

Volumn 2, Issue 1, 2013, Pages

  Basten, Sander G ^a   Willekers, Sven ^a   Vermaat, Joost SP ^a   Slaats, Gisela GG ^a   Voest, Emile E ^a   van Diest, Paul J ^a   Giles, Rachel H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Chromophobe RCC; Cilia; Clear cell renal cell carcinoma; Histology; Kidney; Oncocytoma; Papillary RCC

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; ALPHA TUBULIN; KI 67 ANTIGEN; PERICENTRIN;

ACETYLATION; ARTICLE; AUTOMATION; CANCER PATIENT; CELL DENSITY; CELL NUCLEUS; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; EUKARYOTIC FLAGELLUM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; NEPHRECTOMY; ONCOCYTOMA; PAPILLARY CARCINOMA; PRIORITY JOURNAL; SARCOMATOID CARCINOMA; TISSUE MICROARRAY;

EID: 84893719988     PISSN: None     EISSN: 20462530     Source Type: Journal    
DOI: 10.1186/2046-2530-2-2     Document Type: Article

References (41)

1. Singla V. The primary cilium as the cell's antenna: signaling at a sensory organelle. Science 2006, 313:629-633. 10.1126/science.1124534, 16888132.
2. Oh EC, Katsanis N. Cilia in vertebrate development and disease. Development 2012, 139:443-448. 10.1242/dev.050054, 3275291, 22223675.
3. Hildebrandt F, Benzing T, Katsanis N. Ciliopathies. N Engl J Med 2011, 364:1533-1543. 10.1056/NEJMra1010172, 21506742.
4. Waters AM, Beales PL. Ciliopathies: an expanding disease spectrum. Pediatr Nephrol 2011, 26:1039-1056. 10.1007/s00467-010-1731-7, 3098370, 21210154.
5. Wallingford JB, Mitchell B. Strange as it may seem: the many links between Wnt signaling, planar cell polarity, and cilia. Genes Dev 2011, 25:201-213. 10.1101/gad.2008011, 3034894, 21289065.
6. Lopez-Beltran A, Carrasco JC, Cheng L, Scarpelli M, Kirkali Z, Montironi R. 2009 update on the classification of renal epithelial tumors in adults. Int J Urol 2009, 16:432-443. 10.1111/j.1442-2042.2009.02302.x, 19453547.
7. Takahashi M, Yang XJ, Sugimura J, Backdahl J, Tretiakova M, Qian C-N, Gray SG, Knapp R, Anema J, Kahnoski R, Nicol D, Vogelzang NJ, Furge KA, Kanayama H, Kagawa S, Teh BT. Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene 2003, 22:6810-6818. 10.1038/sj.onc.1206869, 14555994.
8. Yusenko MV. Molecular pathology of chromophobe renal cell carcinoma: a review. Int J Urol 2010, 17:592-600. 10.1111/j.1442-2042.2010.02558.x, 20590942.
9. Yusenko MV. Molecular pathology of renal oncocytoma: a review. Int J Urol 2010, 17:602-612. 10.1111/j.1442-2042.2010.02574.x, 20590944.
10. Mans DA, Voest EE, Giles RH. All along the watchtower: is the cilium a tumor suppressor organelle?. Biochim Biophys Acta 2008, 1786:114-125.
11. Moore LE, Nickerson ML, Brennan P, Toro JR, Jaeger E, Rinsky J, Han SS, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Schmidt LS, Lenz P, Karami S, Linehan WM, Merino M, Chanock S, Boffetta P, Chow W-H, Waldman FM, Rothman N. Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with Germline VHL polymorphisms and etiologic risk factors. PLoS Genet 2011, 7:e1002312. 10.1371/journal.pgen.1002312, 3192834, 22022277.
12. Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J, Choy YS, Reeve MP, Thiele E, Egelhoff JC, Kasprzyk-Obara J, Domanska-Pakiela D, Kwiatkowski DJ. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet 2001, 68:64-80. 10.1086/316951, 1234935, 11112665.
13. Bonsib SM. Renal cystic diseases and renal neoplasms: a mini-review. Clin J Am Soc of Nephrol 2009, 4:1998-2007.
14. Lim DHK, Rehal PK, Nahorski MS, Macdonald F, Claessens T, van Geel M, Gijezen L, Gille JJP, Giraud S, Richard S, van Steensel M, Menko FH, Maher ER. A new locus-specific database (LSDB) for mutations in the folliculin (FLCN) gene. Hum Mutat 2010, 31:E1043-E1051. 10.1002/humu.21130, 19802896.
15. Pavlovich CP, Walther MM, Eyler RA, Hewitt SM, Zbar B, Linehan WM, Merino MJ. Renal tumors in the Birt-Hogg-Dubé syndrome. Am J Surg Pathol 2002, 26:1542-1552. 10.1097/00000478-200212000-00002, 12459621.
16. Mandriota SJ, Turner KJ, Davies DR, Murray PG, Morgan NV, Sowter HM, Wykoff CC, Maher ER, Harris AL, Ratcliffe PJ, Maxwell PH. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 2002, 1:459-468. 10.1016/S1535-6108(02)00071-5, 12124175.
17. Fu L, Wang G, Shevchuk MM, Nanus DM, Gudas LJ. Generation of a mouse model of Von Hippel-Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF1. Cancer Res 2011, 71:6848-6856. 10.1158/0008-5472.CAN-11-1745, 3214086, 21908555.
18. Wilson C, Idziaszczyk S, Parry L, Guy C, Griffiths DF, Lazda E, Bayne RA, Smith AJ, Sampson JR, Cheadle JP. A mouse model of tuberous sclerosis 1 showing background specific early post-natal mortality and metastatic renal cell carcinoma. Hum Mol Genet 2005, 14:1839-1850. 10.1093/hmg/ddi190, 15888477.
19. Baba M, Furihata M, Hong SB, Tessarollo L, Haines DC, Southon E, Patel V, Igarashi P, Alvord WG, Leighty R, Yao M, Bernardo M, Ileva L, Choyke P, Warren MB, Zbar B, Linehan WM, Schmidt LS. Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst 2008, 100:140-154. 10.1093/jnci/djm288, 2704336, 18182616.
20. Bettencourt-Dias M, Hildebrandt F, Pellman D, Woods G, Godinho SA. Centrosomes and cilia in human disease. Trends Genet 2011, 27:307-315. 10.1016/j.tig.2011.05.004, 3144269, 21680046.
21. Nigg EA, Stearns T. The centrosome cycle: centriole biogenesis, duplication and inherent asymmetries. Nat Cell Biol 2011, 13:1154-1160. 10.1038/ncb2345, 21968988.
22. Schraml P, Frew IJ, Thoma CR, Boysen G, Struckmann K, Krek W, Moch H. Sporadic clear cell renal cell carcinoma but not the papillary type is characterized by severely reduced frequency of primary cilia. Mod Pathol 2008, 22:31-36.
23. Kroeze SGC, Vermaat JS, van Brussel A, van Melick HHE, Voest EE, Jonges TGN, van Diest PJ, Hinrichs J, Bosch JLHR, Jans JJM. Expression of nuclear FIH independently predicts overall survival of clear cell renal cell carcinoma patients. Eur J Cancer 2010, 46:3375-3382. 10.1016/j.ejca.2010.07.018, 20709525.
24. van der Ven K, Nguyen TQ, Goldschmeding R. Immunofluorescence on proteinase XXIV-digested paraffin sections. Kidney Int 2007, 72:896.
25. Aperio ImageScope.http://www.aperio.com.
26. Santos N, Reiter JF. Building it up and taking it down: the regulation of vertebrate ciliogenesis. Dev Dyn 2008, 237:1972-1981. 10.1002/dvdy.21540, 3304540, 18435467.
27. Kim J, Dabiri S, Seeley ES. Primary cilium depletion typifies cutaneous melanoma in situ and malignant melanoma. PLoS ONE 2011, 6:e27410. 10.1371/journal.pone.0027410, 3214062, 22096570.
28. Seeley ES, Carrière C, Goetze T, Longnecker DS, Korc M. Pancreatic cancer and precursor pancreatic intraepithelial neoplasia lesions are devoid of primary cilia. Cancer Res 2009, 69:422-430. 10.1158/0008-5472.CAN-08-1290, 2629528, 19147554.
29. Wong SY, Seol AD, So P-L, Ermilov AN, Bichakjian CK, Epstein EH, Dlugosz AA, Reiter JF. Primary cilia can both mediate and suppress Hedgehog pathway-dependent tumorigenesis. Nat Med 2009, 15:1055-1061. 10.1038/nm.2011, 2895420, 19701205.
30. Han Y-G, Kim HJ, Dlugosz AA, Ellison DW, Gilbertson RJ, Alvarez-Buylla A. Dual and opposing roles of primary cilia in medulloblastoma development. Nat Med 2009, 15:1062-1065. 10.1038/nm.2020, 2771737, 19701203.
31. Lolkema MP, Mans DA, Snijckers CM, van Noort M, van Beest M, Voest EE, Giles RH. The von Hippel-Lindau tumour suppressor interacts with microtubules through kinesin-2. FEBS Letters 2007, 581:4571-4576. 10.1016/j.febslet.2007.08.050, 17825299.
32. Frew IJ, Thoma CR, Georgiev S, Minola A, Hitz M, Montani M, Moch H, Krek W. pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation. EMBO J 2008, 27:1747-1757. 10.1038/emboj.2008.96, 2435131, 18497742.
33. Thoma CRC, Frew IJI, Krek WW. The VHL tumor suppressor: riding tandem with GSK3beta in primary cilium maintenance. Cell Cycle 2007, 6:1809-1813. 10.4161/cc.6.15.4518, 17671433.
34. Tee AR, Pause A. Birt-Hogg-Dubé: tumour suppressor function and signalling dynamics central to folliculin. Fam Cancer 2012, [Epub ahead of print].
35. Basten SG, Haidari K, Slaats G, van Steensel M, Giles R. 3D renal modeling classifies BHD as a ciliopathy, possibly responsive to treatment with PTC124. Cilia 2012, (Suppl 1):82.
36. Hartman TR, Liu D, Zilfou JT, Robb V, Morrison T, Watnick T, Henske EP. The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycin-insensitive and polycystin 1-independent pathway. Hum Mol Genet 2008, 18:151-163. 10.1093/hmg/ddn325, 2644647, 18845692.
37. Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 2010, 7:277-285. 10.1038/nrurol.2010.47, 2929006, 20448661.
38. Kaelin WG. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002, 2:673-682. 10.1038/nrc885, 12209156.
39. Yuan S, Li J, Diener DR, Choma MA, Rosenbaum JL, Sun Z. Target-of-rapamycin complex 1 (Torc1) signaling modulates cilia size and function through protein synthesis regulation. Proc Natl Acad of Sci USA 2012, 109:2021-2026.
40. Boehlke C, Kotsis F, Patel V, Braeg S, Voelker H, Bredt S, Beyer T, Janusch H, Hamann C, Gödel M, Müller K, Herbst M, Hornung M, Doerken M, Köttgen M, Nitschke R, Igarashi P, Walz G, Kuehn EW. Primary cilia regulate mTORC1 activity and cell size through Lkb1. Nat Cell Biol 2010, 12:1115-1122. 10.1038/ncb2117, 3390256, 20972424.
41. Hassounah NB, Bunch TA, McDermott KM. Molecular pathways: the role of primary cilia in cancer progression and therapeutics with a focus on hedgehog signaling. Clin Cancer Res 2012, 18:2429-2435. 10.1158/1078-0432.CCR-11-0755, 22415315.